Antagonists of neuropilin receptor function and use thereof

Details Antagonists of neuropilin receptor function and use thereof Antagonists of neuropilin receptor function and use thereof

2002-03-22

2010-06-08

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Reexamination Certificate

active

07731959

ABSTRACT:
The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

REFERENCES:
patent: 6617160 (2003-09-01), Shitara et al.
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
MSNBC News Services, “Mixed results on new cancer drug”, Nov. 9, 2000.
Gura (Science, v278, 1997, pp. 1041-1042).
Basile et al. (2004, Cancer Research 64:5212-5224).
Neufeld (2005, Frontiers in Bioscience 10:751-760).
Muller et al. (1996, Current Opinion in Genetics and Development 6(4):469-474) (abstract only).
J. K. Kim et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth In Vivo,” Nature, 362(6423) 841-844, 1993.
M. Klagsbrun et al., “VEGF/VPF: The Angiogenesis Factor Found?” Current Biology, 3(1):699-702, 1993.
Z. Poltorak et al., “VEGF145, A Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular Matrix,” J. Biol. Chem., 272(11) 7151-7158, 1997.
H. Chen et al., “Neuropilin-2, A Novel Member of the Neuropilin Family, is a High Affinity receptor for the Semaphorins Sema E and Sema IV but not Sema III,”Neuron, 19:547-559, 1997.
A. L. Kolodkin et al., “Neuropilin is a Semaphorin III Receptor,” Cell, 90:753-762, 1997.
FDA News. “FDA Approves First Angiogenesis Inhibitor to Treat Colorectal Cancer” http://www.fda.gov/bbs/topics/NEWS/2004/NEW01027.html, P04-23 (Feb. 26, 2004).
Ferrara, et al. “Angiogenesis as a therapeutic target”Nature438: 967-974 (2005).
He, et al. “Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III”Cell90:739-751 (1997).
Kowanetz, et al. “Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective”Clinical Cancer Res.12(17): 5018-5022 (2006).
Li, et al. “Pancreatic Carcinoma Cells Express Neuropilins and Vascular Endothelial Growth Factor, but Not Vascular Endothelial Growth Factor Receptors”Wiley InterScience(2004).
Liang, et al. “Function Blocking Antibodies to Neuropilin-1 Generated from a Designed Human Synthetic Antibody Phage Library”J. Mol. Biol.(2006).
Pan, et al. “Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth”Cancer Cell11: 53-67 and Supplemental Data (2007).
Shojaei, et al. “Antiangiogenesis to treat cancer and intraocular neovascular disorders”Laboratory Investigation87: 227-230 (2007).
Jaalouk, D.E. et al., Cancer Res, 67(20):9623-9629 (2007). “The Original Pathologische Anatomie Leiden-Endothelium Monocloncal Antibody Recognizes a Vascular Endothelial Growth Factor-Binding Site Within Neuropilin-1.”

Affiliated with

Also associated with

Rating

Antagonists of neuropilin receptor function and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonists of neuropilin receptor function and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of neuropilin receptor function and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4190443